A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
NCT06727630
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
PRJ1-3024
Sponsor
Zhuhai Yufan Biotechnologies Co., Ltd